Phase 1 clinical trial has been completed in age groups ranging from 18 to 60 years, it said. “Bharat Biotech’s intranasal vaccine is the first nasal vaccine that has received the regulatory approval for phase 2 trials,” the DBT said in a revised statement. In a statement issued earlier, the DBT had said the regulator’s nod was given for phase 2 and 3 clinical trials.